RT Journal Article
SR Electronic
T1 Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent Covid-19 – a prospective multicentre cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.09.21258422
DO 10.1101/2021.06.09.21258422
A1 Philipp Kohler
A1 Sabine Güsewell
A1 Marco Seneghini
A1 Thomas Egger
A1 Onicio Leal
A1 Angela Brucher
A1 Eva Lemmenmeier
A1 J. Carsten Möller
A1 Philip Rieder
A1 Markus Ruetti
A1 Reto Stocker
A1 Danielle Vuichard-Gysin
A1 Benedikt Wiggli
A1 Ulrike Besold
A1 Stefan P. Kuster
A1 Allison McGeer
A1 Lorenz Risch
A1 Andrée Friedl
A1 Pietro Vernazza
A1 Christian R. Kahlert
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258422.abstract
AB Objectives In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus.Methods Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with Coronavirus Disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies.Results A total of 4’818 HCW participated, whereof 144 (3%) were seropositive at baseline. We analysed 107’820 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P=0.83) between those with and without positive baseline serology. Among 2’713 HCW with ≥1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2646 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95%-CI: 0.15-0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95%-CI: 0.39-0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95%-CI: 0.49-0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results.Conclusions Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least eight months.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSwiss National Sciences Foundation, Federal Office of Public Health, Cantonal Health Department St.GallenAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Eastern Switzerland (#2020-00502).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author upon reasonable request.